MedTrace Logo

Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors

NCT04064294 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 93

Last updated 2025-04-11

Study results available
· View outcomes & findings →

Summary

In this study, the investigators will examine the association of statin use and dyskinesia in a convenience sample Parkinson's disease patients in the Veterans Administration Health Care System.

Conditions

  • Parkinson Disease
  • Dyskinesia, Drug-Induced

Interventions

DRUG

Intravenous Infusion

Intravenous levodopa given 1.0 to 1.5 mg/kg/hr from 0930 - 1130 on a single visit day.

Sponsors & Collaborators

  • Oregon Health and Science University

    collaborator OTHER

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Kathryn Anne Chung, MD · VA Portland Health Care System, Portland, OR

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-22
Primary Completion
2024-03-31
Completion
2024-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04064294 on ClinicalTrials.gov